BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment

BRACAnalysis CDx Approved in US as Companion Diagnostic Test for First-line Lynparza Treatment
Myriad Genetics‘ BRACAnalysis CDx has been approved by the U.S. Food and Drug Administration as a companion diagnostic test to identify women with ovarian cancer eligible for first-line maintenance treatment with Lynparza (olaparib). Lynparza was recently approved for patients who had a partial or complete response to first-line platinum-based chemotherapy and have inherited mutations in their BRCA genes. BRACAnalysis

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *